Betta Pharma

Betta Pharma, founded 2003 in Hangzhou, develops and markets oncology drugs in China, including the EGFR inhibitor Icotinib and anti‑VEGF Bevacizumab, with a robust pipeline of TKIs, antibodies, and kinase inhibitors targeting NSCLC and solid tumors.

Headquarters: China (CHN)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

HQ: Hangzhou

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
300558	Betta Pharma Rg-Class A Cap: 20.7B \| P/E: 68.3	EQUITY	SHZ	CNY	CNE100002DD9	Active	📈